Citations

Clear

421 citation(s) found for "Short, C".

Outpatient Motor Retraining for Functional Movement Disorder: Predictors of a Favorable Short‐Term Response
Callister, Marcus N. , Klanderman, Molly , Boddu, Sayi P. , Moutvic, Margaret A., Geissler, Elizabeth N., Traver, Katie J., Hassan, Anhar , Klanderman, Molly C, Boddu, Sayi , Staab, Jeffrey P.

Mayo Clinic

Movement Disorders Clinical Practice | July 14, 2023 | Volume: 10 | Issue: 9 | Pages: 1377-1387

10.1002/mdc3.13844 | PMID 37772308 Get It

ABSTRACTBackgroundTreating functional movement disorder (FMD) with motor retraining is effective but resource intensive.ObjectivesIdentify patient, disease, and program variables associated with favorable treatment outcomes.MethodsRetrospective review of the 1 week intensive outpatient FMD program at Mayo Clinic in Minnesota from February 2019 to August 2021. Outcomes included patient‐reported measures (Canadian Occupational Performance Measure‐Performance and Satisfaction subscales [COPM‐P and COPM‐S, range 0–10] and Global Rating of Change [GROC, −7 to +7]) and a retrospective investigator‐rated scale (0–3, worse/not improved to significantly improved/resolved). Linear regression models identified variables predicting favorable outcomes.ResultsParticipants (n = 201, 74% female, mean age = 46) had median FMD duration of 24 months. The commonest FMD subtypes were gait disorder (65%), tremor (41%) and weakness (17%); 53% had ≥2 subtypes. Most patients (88%) completed a therapeutic screening process before program entry. Patient‐reported outcomes at the end of the week improved substantially (COPM‐P average change 3.8 ± 1.9; GROC post‐program average 5.5 ± 1.7). Available investigator‐rated outcomes from short‐term follow‐up were also positive (102/122 [84%] moderately to significantly improved/resolved). Factors predicting greater improvement in COPM‐P were completing therapeutic screening, higher number of non‐motor symptoms, shorter FMD duration, earlier program entry, lower baseline COPM scores, and (among screened patients) higher GROC between therapeutic screening and program start.ConclusionPatients with diverse FMD subtypes improved substantially over a 1 week period. Utilization of therapeutic screening and greater improvement between therapeutic screening and program start were novel predictors of favorable outcomes. Non‐motor symptoms did not preclude positive responses, although patients with predominant non‐motor burden were excluded.
LGG-01. DEVELOPMENT OF A WEB-BASED CALCULATOR APPLICATION FOR PREDICTING SHORT- AND LONG-TERMSURVIVAL IN PEDIATRIC OPTIC PATHWAY GLIOMA: A POPULATION-BASED DATABASE ANALYSIS
Brown, Nolan J. , Kuo, Cathleen C. , Givens, Drew, Pennington, Zach , Gendreau, Julian , Daniels, David J.

Mayo Clinic

Neuro-Oncology | June 12, 2023 | Volume: 25 | Issue: Supplement_1 | Pages: i54-i55

10.1093/neuonc/noad073.211 Get It

Abstract Optic pathway gliomas (OPG) are generally low-grade lesions arising from the astrocytes of the visual pathway, most commonly of the optic nerves and chiasm. Uncertainty remains regarding the optimal management of this patient population. We sought to leverage population-level data from the Surveillance, Epidemiology, and End Results program database to develop a predictive calculator for overall survival (OS) amongst pediatric patients with OPG. A total of 1,052 patients who had been diagnosed with OPG were included. Multivariate cox proportional hazard model demonstrated patients of “other” race (hazard ratio [HR]=4.109, 95% confidence interval [CI] 1.076-15.694, p=0.039) exhibited a decreased overall survival, while patients with a median household income ≥$55,000 (HR=0.172, 95% CI 0.065-0.457, <0.001) and those who underwent subtotal resection (HR=3.549, 95% CI 1.092-13.364, p=0.047) had a higher overall survival rate. An online, interactive survival prediction tool (https://spine.shinyapps.io/optic_glioma/) was created to estimate 5-, 10-, and 15-year overall survival probability as well as median survival months. C-index was 0.722 (95% CI 0.642-0.776) for the training set and 0.745 (95% CI 0.661-0.790) for the validation set. Good concordance between the predicted probability and the actual probability of the dataset was also observed. This calculator may serve as a useful clinical tool during patient counseling. Further investigations aimed at developing calculators of visual acuity preservation and progression-free survival are merited; progress toward this end will benefit from continued multicenter collaborations.
Novel Standalone Motion-Sparing Pelvic Fixation Prevents Short-Term Insufficiency Fractures After Midsacrectomies Without Sacrificing Normal, Mobile Lumbar Segments Traditionally Used for Stabilization
Lo, Sheng-Fu Larry , Pieters, Thomas A. , Green, Ross, Suk, Ian, Pennington, Zach , Elsamadicy, Aladine A. , Sciubba, Daniel M. , Pennington, Zach , Hersh, Andrew M.

Mayo Clinic

Operative Neurosurgery | June 7, 2023 | Volume: 25 | Issue: 3 | Pages: 278-284

10.1227/ons.0000000000000767 | PMID 37278692 Get It

BACKGROUND AND OBJECTIVES: Sacrectomy is often the treatment of choice to provide the greatest chance of progression-free and overall survival for patients with primary malignant bone tumors of the sacrum. After midsacrectomy, the stability of the sacropelvic interface is diminished, resulting in insufficiency fractures. Traditional stabilization involves lumbopelvic fixation but subjects normal mobile segments to fusion. The purpose of this study was to determine whether standalone intrapelvic fixation is a safe adjunct to midsacrectomy, avoiding both sacral insufficiency fractures and the morbidity of instrumenting into the mobile spine. METHODS: A retrospective study identified all patients who underwent resection of sacral tumors at 2 comprehensive cancer centers between June 2020 and July 2022. Demographic, tumor-specific, operative characteristics and outcome data were collected. The primary outcome was presence of sacral insufficiency fractures. A retrospective data set of patients undergoing midsacrectomy without hardware placement was collected as a control. RESULTS: Nine patients (5 male, 4 female), median age 59 years, underwent midsacrectomy with concomitant placement of standalone pelvic fixation. No patients developed insufficiency fractures during the 216 days of clinical and 207 days of radiographic follow-up. There were no adverse events attributable to the addition of standalone pelvic fixation. In our historical cohort of partial sacrectomies without stabilization, there were 4/25 patients (16%) with sacral insufficiency fractures. These fractures appeared between 0 and 5 months postoperatively. CONCLUSION: A novel standalone intrapelvic fixation after partial sacrectomy is a safe adjunct to prevent postoperative sacral insufficiency fractures in patients undergoing midsacrectomy for tumor. Such a technique may allow for long-term sacropelvic stability without sacrificing mobile lumbar segments.
Phase II study of short course hypofractionated proton beam therapy incorporating 18F-DOPA-PET/MRI for elderly patients with newly diagnosed glioblastoma.
Vora, Sujay A., Pafundi, Deanna, Voss, Molly M., Ashman, Jonathan B. , Bendock, Bernard, Mahajan, Anita , Mrugała, Maciej M. , Porter, Alyx B. , Ruff, Michael W. , Uhm, Joon H. , Brinkmann, Debra H. , Yang, Ming , Brown, Paul D. , DeWees, T.A. , Laack, Nadia N. , Liu, Wei , Sio, Terence T.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 2002-2002

10.1200/jco.2023.41.16_suppl.2002 Get It

2002 Background: Elderly patients with glioblastoma have a poor prognosis with phase III trials reporting median overall survival (OS) and global time to deterioration of 6–9 and 1.2 months respectively. 18F-DOPA (3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine) positron emission tomography (PET) is sensitive and specific for identifying regions of high density and biologically aggressive glioblastoma. Proton beam therapy (PBT) can spare more healthy tissue that may improve quality of life for this patient population. With improved targeting of disease along with dosimetric advantages of PBT, this phase II trial tested whether hypofractionated PBT can offer both improved survival and quality of life. Methods: Patients with newly diagnosed glioblastoma aged ≥65 years without contraindications to 18F-DOPA were eligible. Target volumes were defined by PET (tumor/normal brain SUV ≥2.0) and MRI areas of contrast enhancement including surgical cavity. Patients received dose escalated hypofractionated PBT of 35-40 GyE to PET/MRI over 5-10 treatments with 10 mm margin. Patients received concurrent/adjuvant temozolomide. With an alpha of 0.1, 18 of 39 patients would be required to be alive at 12 months for the study to be considered a success. Kaplan-Meier/Cox regression analysis was performed for progression free survival (PFS) and OS. Toxicities were evaluated with CTCAE v4.0. Patients completed EORTC BN20, QLQ-C30, and MMSE questionnaires. Time to deterioration, defined as a 10-point decrease in the score of the function domain or 10-point increase in score of symptom domain, was evaluated. Results: Between 5/2019-6/2021, 43 patients were enrolled, with 4 patients withdrawing due to progression/insurance denial prior to beginning protocol therapy. The median age was 70.2 yrs. and median follow-up was 12.5 months. MGMT methylation was present in 13 (33%). Tumors were multifocal in 10 (26%) and unifocal in 29 (74%). The primary endpoint was met with median PFS/OS was 6.5/12.9 months for all patients and for MGMT methylated patients 11.9/29.8 months respectively. Grade 3 baseline adjusted treatment related adverse events included 1 (3%) confusion, 2 (5%) fatigue, and 1 (3%) seizure. There were no grade 4/5 events. Multivariate analysis revealed MGMT unmethylated, ECOG 2 and biopsy only patients had worse survival. PET volume was more predictive than MRI volume for OS with PET volume>26 cc having a hazard ratio of 3.7. The median time to global deterioration per QLC-C30 was 6.3 months. Conclusions: This phase II trial incorporating 18F-DOPA PET-guided dose escalated hypofractionated proton beam treatment for elderly patients with glioblastoma met its primary endpoint for improved OS and patient reported quality of life compared to historical controls. Further investigation is warranted. Clinical trial information: NCT03778294 .
Management and Outcomes of Wilms Tumor With Suprarenal Intravascular Extension
Naik‐Mathuria, Bindi , Dasgupta, Roshni , Short, Scott S. , Lovvorn, Harold N. , Newman, Erica, Rich, Barrie S. , Piché, Nelson , Glick, Richard D. , Petroze, Robin T. , Polites, Stephanie F. , Alore, Elizabeth , Sutthatarn, Pattamon , Wong‐Michalak, Shannon , Romao, Rodrigo , Al‐Hadidi, Ameer , Marquart, John , Gainer, Hailey, Johnson, Mike, Boehmer, Chloé , Rinehardt, Hannah , Seemann, Natashia M. , Davidson, Jacob , Polcz, Valerie E., Lund, Sarah , McKay, Katlyn G. , Correa, Hernán , Lund, Sarah B, Dasgupta, Roshni , Utria, Alan Fremder , Ehrlich, Peter F. , Aldrink, Jennifer H. , Murphy, Andrew J. , Lautz, Timothy B. , Kim, Eugene S. , Lal, Dave R. , Kastenberg, Zachary J. , Malek, Marcus M. , Whitlock, Richard S. , Chen, Stephanie , Rubalcava, Nathan S. , Gainer, Hailey, Rothstein, David H.

Mayo Clinic

Annals of Surgery | June 2, 2023 | Volume: 279 | Issue: 3 | Pages: 528-535

10.1097/sla.0000000000005921 | PMID 37264925 Get It

Objective: The purpose of this study was to describe management and outcomes from a contemporary cohort of children with Wilms tumor complicated by inferior vena caval thrombus. Background: The largest series of these patients was published almost 2 decades ago. Since then, neoadjuvant chemotherapy has been commonly used to manage these patients, and outcomes have not been reported. Methods: Retrospective review of 19 North American centers between 2009 and 2019. Patient and disease characteristics, management, and outcomes were investigated and analyzed. Results: Of 124 patients, 81% had favorable histology (FH), and 52% were stage IV. IVC thrombus level was infrahepatic in 53 (43%), intrahepatic in 32 (26%), suprahepatic in 14 (11%), and cardiac in 24 (19%). Neoadjuvant chemotherapy using a 3-drug regimen was administered in 82% and postresection radiation in 90%. Thrombus level regression was 45% overall, with suprahepatic level showing the best response (62%). Cardiopulmonary bypass (CPB) was potentially avoided in 67%. The perioperative complication rate was significantly lower after neoadjuvant chemotherapy [(25%) vs upfront surgery (55%); P=0.005]. CPB was not associated with higher complications [CPB (50%) vs no CPB (27%); P=0.08]. Two-year event-free survival was 93% and overall survival was 96%, higher in FH cases (FH 98% vs unfavorable histology/anaplastic 82%; P=0.73). Neither incomplete resection nor viable thrombus cells affected event-free survival or overall survival. Conclusions: Multimodal therapy resulted in excellent outcomes, even with advanced-stage disease and cardiac extension. Neoadjuvant chemotherapy decreased the need for CPB to facilitate resection. Complete thrombectomy may not always be necessary.
Outcomes of Short‐Term Surgical Trips in Otolaryngology—Head and Neck Surgery: A Scoping Review
Wiedermann, Josh, Douse, Dontre’ M. , Green, Katerina J. , Pang, Jonathan C. , Blount, Quinton, Yu, Karina, Wiedermann, Joshua , Green, Katerina , Pang, Jonathan C , Shrime, Mark G.

Mayo Clinic

The Laryngoscope | May 30, 2023 | Volume: 134 | Issue: 1 | Pages: 32-39

10.1002/lary.30764 | PMID 37249184 Get It

ObjectiveThis scoping review aims to explore the current body of literature to characterize how short‐term surgical trips (STSTs) in Otolaryngology‐Head and Neck Surgery (OtoHNS) contribute to surgical, educational, and sustainability‐based outcomes in low‐ and middle‐income countries (LMICs). We aim to use these data to synthesize aspects of STSTs that are successful with the hopes of shaping future global efforts.Data SourcesData sources included Ovid MEDLINE, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus.Review MethodsA comprehensive search was conducted on several databases from inception to October 14, 2021. We included primary studies exploring any surgical or educational outcomes of global short‐term surgical endeavors within LMICs. Data were then extracted to evaluate the heterogenous body of literature that exists, characterizing the surgical, educational, and sustainability‐based outcomes.ResultsForty‐Seven studies were included in the final analysis. Most publications were focused on surgical interventions (39 of 47; 82.9%); 13 (27.7%) studies included education as the primary aim and 12 (25.5%) considered sustainability a significant aim. Of the 94 first and last authors, there were zero first authors and only one last author with an LMIC affiliation. Twenty‐six studies (55%) mentioned that any patients were seen in follow‐up, ranging from one day to five years.ConclusionOur scoping review demonstrates that most STSTs have focused primarily on surgical procedures with a lack of appropriate long‐term follow‐up. However, the available outcome‐based information presented helps identify factors that characterize a strong short‐term global surgical program.Level of EvidenceNA Laryngoscope, 134:32–39, 2024
Short-Term Outcomes of Heart Transplant Patients Bridged with Impella 5.5 Ventricular Assist Device
Haddad, Osama , Sareyyüpoğlu, Başar , Goswami, Rohan , Bitargil, Macit , Patel, Parag C. , Jacob, Samuel , Ahmed, Magdy M. El‐Sayed , Leoni, Juan , Yip, Daniel , Landolfo, Kevin , Leoni Moreno, Juan Carlos, Pham, Si M. , Goswami, Rohan , Leoni, Juan Carlos

Mayo Clinic

ESC Heart Failure | May 3, 2023 | Volume: 10 | Issue: 4 | Pages: 2298-2306

10.1002/ehf2.14391 | PMID 37137732 Get It

Abstract Aims We sought to investigate the outcomes of heart transplant patients supported with Impella 5.5 temporary mechanical circulatory support. Methods and results Patient demographics, perioperative data, hospital timeline, and haemodynamic parameters were followed during initial admission, Impella support, and post-transplant period. Vasoactive-inotropic score, primary graft failure, and complications were recorded. Between March 2020 and March 2021, 16 advanced heart failure patients underwent Impella 5.5 temporary left ventricular assist device support through axillary approach. Subsequently, all these patients had heart transplantation. All patients were either ambulatory or chair bound during their temporary mechanical circulatory support until heart transplantation. Patients were kept on Impella support median of 19 days (3–31) with the median lactate dehydrogenase level of 220 (149–430). All Impella devices were removed during heart transplantation. During Impella support, patients had improved renal function with median creatinine serum level of 1.55 mg/dL decreased to 1.25 (P = 0.007), pulmonary artery pulsatility index scores increased from 2.56 (0.86–10) to 4.2 (1.3–10) (P = 0.048), and right ventricular function improved (P = 0.003). Patients maintained improved renal function and favourable haemodynamics after their heart transplantation as well. All patients survived without any significant morbidity after their heart transplantation. Conclusions Impella 5.5 temporary left ventricular assist device optimizes care of heart transplant recipients providing superior haemodynamic support, mobility, improved renal function, pulmonary haemodynamics, and right ventricular function. Utilizing Impella 5.5 as a direct bridging strategy to heart transplantation resulted in excellent outcomes.
Short Term Outcomes and Factors Associated Treatment Response in Fibrotic Hypersensitivity Pneumonitis
Pornchai, A., Moua, Teng , Petnak, Tananchai , Thongprayoon, Charat

Mayo Clinic

A39. MANAGEMENT OF INTERSTITIAL LUNG DISEASE AND ITS CO-MORBIDITIES | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A1524-A1524

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1524 Get It

Short bowel syndrome: Complications and management
Bering, Jamie , DiBaise, John K.

Mayo Clinic

Nutrition in Clinical Practice | April 28, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1002/ncp.10978 | PMID 37115034 Get It

AbstractShort bowel syndrome (SBS) occurs when a patient loses bowel length or function significantly enough to cause malabsorption, oftentimes requiring lifelong parenteral support. In adults, this occurs most commonly in the setting of massive intestinal resection, whereas congenital anomalies and necrotizing enterocolitis predominate in children. Many patients with SBS develop long‐term clinical complications over time related to their altered intestinal anatomy and physiology or to various treatment interventions such as parenteral nutrition and the central venous catheter through which it is administered. Identifying, preventing, and treating these complications can be challenging. This review will focus on the diagnosis, treatment, and prevention of several complications that can occur in this patient population, including diarrhea, fluid and electrolyte imbalance, vitamin and trace element derangements, metabolic bone disease, biliary disorders, small intestinal bacterial overgrowth, d‐lactic acidosis, and complications of central venous catheters.
Short bowel syndrome: Recognizing unmet needs
DiBaise, John K.

Mayo Clinic

Nutrition in Clinical Practice | April 28, 2023 | Volume: 38 | Issue: S1 | Pages: No page available

10.1002/ncp.10948 | PMID 37115035 Get It